The Role of Immune Cells in the Course of Parkinson's Disease

Overview

Journal Ibrain

Specialty Neurology

Date 2023 Oct 3

PMID 37786903

Authors

Xiu-Ying He

Ru-Rong Wang

Ting-Hua Wang

Affiliations

Soon will be listed here.

Abstract

Parkinson's disease (PD) is a common neurodegenerative disease in the central nervous system. The pathological manifestations mainly consist of α-synuclein accumulation, degeneration and death of dopaminergic neurons, and insufficient dopamine secretion. There are many pathophysiological mechanisms leading to these pathological changes. The role of autoimmunity in Parkinson's disease is one of the academic hotspots in recent years. Many types of immune cells actively participate in the pathogenesis of Parkinson's disease, such as dendritic cells, microglia, T lymphocytes, B lymphocytes and natural killer (NK) cells, which lead to abnormal immune response in Parkinson's disease patients. Therefore, this paper focuses on reviewing the research progress of immune cells in Parkinson's disease.

References

Goldeck D, Maetzler W, Berg D, Oettinger L, Pawelec G . Altered dendritic cell subset distribution in patients with Parkinson's disease: Impact of CMV serostatus. J Neuroimmunol. 2015; 290:60-5. DOI: 10.1016/j.jneuroim.2015.11.008. View

Labrie V, Brundin P . Alpha-Synuclein to the Rescue: Immune Cell Recruitment by Alpha-Synuclein during Gastrointestinal Infection. J Innate Immun. 2017; 9(5):437-440. PMC: 5607025. DOI: 10.1159/000479653. View

Stevens C, Rowe D, Morel-Kopp M, Orr C, Russell T, Ranola M . Reduced T helper and B lymphocytes in Parkinson's disease. J Neuroimmunol. 2012; 252(1-2):95-9. DOI: 10.1016/j.jneuroim.2012.07.015. View

Chen Y, Yu M, Liu X, Qu H, Chen Q, Qian W . Clinical characteristics and peripheral T cell subsets in Parkinson's disease patients with constipation. Int J Clin Exp Pathol. 2015; 8(3):2495-504. PMC: 4440064. View

Kalia L, Lang A . Parkinson's disease. Lancet. 2015; 386(9996):896-912. DOI: 10.1016/S0140-6736(14)61393-3. View

Collins L, Toulouse A, Connor T, Nolan Y . Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease. Neuropharmacology. 2012; 62(7):2154-68. DOI: 10.1016/j.neuropharm.2012.01.028. View

Davie C . A review of Parkinson's disease. Br Med Bull. 2008; 86:109-27. DOI: 10.1093/bmb/ldn013. View

Appel S, Beers D, Henkel J . T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening?. Trends Immunol. 2009; 31(1):7-17. PMC: 4126423. DOI: 10.1016/j.it.2009.09.003. View

Kustrimovic N, Comi C, Magistrelli L, Rasini E, Legnaro M, Bombelli R . Parkinson's disease patients have a complex phenotypic and functional Th1 bias: cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-naïve and drug-treated patients. J Neuroinflammation. 2018; 15(1):205. PMC: 6044047. DOI: 10.1186/s12974-018-1248-8. View

10.

Jiang T, Li G, Xu J, Gao S, Chen X . The Challenge of the Pathogenesis of Parkinson's Disease: Is Autoimmunity the Culprit?. Front Immunol. 2018; 9:2047. PMC: 6170625. DOI: 10.3389/fimmu.2018.02047. View

11.

Korin B, Ben-Shaanan T, Schiller M, Dubovik T, Azulay-Debby H, Boshnak N . High-dimensional, single-cell characterization of the brain's immune compartment. Nat Neurosci. 2017; 20(9):1300-1309. DOI: 10.1038/nn.4610. View

12.

Zhang Y, Feng S, Nie K, Li Y, Gao Y, Gan R . TREM2 modulates microglia phenotypes in the neuroinflammation of Parkinson's disease. Biochem Biophys Res Commun. 2018; 499(4):797-802. DOI: 10.1016/j.bbrc.2018.03.226. View

13.

Jiang S, Gao H, Luo Q, Wang P, Yang X . The correlation of lymphocyte subsets, natural killer cell, and Parkinson's disease: a meta-analysis. Neurol Sci. 2017; 38(8):1373-1380. DOI: 10.1007/s10072-017-2988-4. View

14.

Caggiu E, Paulus K, Galleri G, Arru G, Manetti R, Sechi G . Homologous HSV1 and alpha-synuclein peptides stimulate a T cell response in Parkinson's disease. J Neuroimmunol. 2017; 310:26-31. DOI: 10.1016/j.jneuroim.2017.06.004. View

15.

. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016; 388(10053):1545-1602. PMC: 5055577. DOI: 10.1016/S0140-6736(16)31678-6. View

16.

Harms A, Cao S, Rowse A, Thome A, Li X, Mangieri L . MHCII is required for α-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. J Neurosci. 2013; 33(23):9592-600. PMC: 3903980. DOI: 10.1523/JNEUROSCI.5610-12.2013. View

17.

Baba Y, Kuroiwa A, Uitti R, Wszolek Z, Yamada T . Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat Disord. 2005; 11(8):493-8. DOI: 10.1016/j.parkreldis.2005.07.005. View

18.

Cancela J, Pastorino M, Arredondo M, Nikita K, Villagra F, Pastor M . Feasibility study of a wearable system based on a wireless body area network for gait assessment in Parkinson's disease patients. Sensors (Basel). 2014; 14(3):4618-33. PMC: 4003960. DOI: 10.3390/s140304618. View

19.

Gruden M, Sewell R, Yanamandra K, Davidova T, Kucheryanu V, Bocharov E . Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression. J Neuroimmunol. 2011; 233(1-2):221-7. DOI: 10.1016/j.jneuroim.2010.12.001. View

20.

Bokor M, Farago A, Garam T, Malatinszky G, Schnabel R . Antibody-dependent cell-mediated cytotoxicity (ADCC) in Parkinson's disease. J Neurol Sci. 1993; 115(1):47-50. DOI: 10.1016/0022-510x(93)90065-7. View